Company profile: Floragenex
1.1 - Company Overview
Company description
- Provider of innovative genomic analysis solutions for human, plant, and animal systems. Oregon-based privately owned biotechnology company delivering results in hundreds of genomics studies since 2007, supporting research in genetics, ecology, evolutionary biology, and biomedical fields.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Floragenex
RareCyte
HQ: United States
Website
- Description: Provider of rare cell characterization and isolation solutions for life science research and diagnostic development, including the Orion Platform for whole slide multimodal imaging in spatial biology and biomarker quantitation; CyteFinder II for high-speed imaging with multiplexed liquid biopsy and tissue spatial analysis and single-cell or tissue micro-region retrieval; AccuCyte for isolating circulating tumor cells; Precision Biology Services; and customizable Orion biomarker panels for FFPE or frozen tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RareCyte company profile →
Psomagen
HQ: United States
Website
- Description: Provider of genomics services for research, clinical, and direct-to-consumer applications, including whole genome sequencing, targeted sequencing, Illumina-compatible library runs as flow cell or lane units with full quality control and sample multiplexing, and genetic testing panels to identify gene, chromosome, or protein changes to help confirm or rule out genetic conditions and assess disease risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Psomagen company profile →
Azitra
HQ: United States
Website
- Description: Provider of microbiome-based dermatology therapeutics and consumer products, offering bioengineered live biotherapeutic candidates ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and protein candidate ATR-01 for ichthyosis vulgaris; and a microbiome dermatology platform to develop products for skin disease treatment and skin appearance improvement; plus topical ointments and creams for dryness, redness, flakiness, and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azitra company profile →
GenturaDx
HQ: United States
Website
- Description: Provider of molecular diagnostic solutions focused on making multiplexed molecular testing affordable and practical for any laboratory to perform. Offers the IDbox system and single-use cassette designed to circumvent barriers of cost, automation and performance, facilitating in-house lab testing for actionable results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenturaDx company profile →
Genable Technologies
HQ: Ireland
Website
- Description: Provider of gene medicines to treat "dominant" genetic diseases, developed by a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company, based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genable Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Floragenex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Floragenex
2.2 - Growth funds investing in similar companies to Floragenex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Floragenex
4.2 - Public trading comparable groups for Floragenex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →